Clinical evaluation of two new antidepressants.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001977:Brompheniramine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011725:Pyridines / Q000627:therapeutic use*; D014196:Trazodone / Q000009:adverse effects / Q000627:therapeutic use*; D015031:Zimeldine
D000928:Antidepressive Agents; D010879:Piperazines; D011725:Pyridines; D015031:Zimeldine; D001977:Brompheniramine; D007099:Imipramine; D014196:Trazodone